Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 639Metabolism, Diabetes, and CancerPI3K/AKT/mTOR signaling in cancerCancer, Hypoxia, and Metabolism

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1

Ben Sahra, Isaam, Regazzetti, Claire, Robert, Guillaume, Laurent, Kathiane, Le Marchand-Brustel, Yannick, Auberger, Patrick, Tanti, Jean-François, Giorgetti-Peraldi, Sophie, Bost, Frédéric·2011·Cancer Research

Published version of a preprint

Abstract

Metformin is a widely prescribed antidiabetic drug associated with a reduced risk of cancer. Many studies show that metformin inhibits cancer cell viability through the inhibition of mTOR. We recently showed that antiproliferative action of metformin in prostate cancer cell lines is not mediated by AMP-activated protein kinase (AMPK). We identified REDD1 (also known as DDIT4 and RTP801), a negative regulator of mTOR, as a new molecular target of metformin. We show that metformin increases REDD1 expression in a p53-dependent manner. REDD1 invalidation, using siRNA or REDD1−/− cells, abrogates metformin inhibition of mTOR. Importantly, inhibition of REDD1 reverses metformin-induced cell-cycle arrest and significantly protects from the deleterious effects of metformin on cell transformation. Finally, we show the contribution of p53 in mediating metformin action in prostate cancer cells. These results highlight the p53/REDD1 axis as a new molecular target in anticancer therapy in response to metformin treatment. Cancer Res; 71(13);4366–72. ©2011 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-10-1769

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 20 references

Cited by

See all 639

Metadata

Authors
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F.
Affiliations
  • Authors' Affiliations: 1“Cellular and Molecular Physiopathology of Obesity and Diabetes” and 2“Cell Death, Differentiation and Cancer” Teams, INSERM U895, C3M, University of Nice Sophia-Antipolis, Faculty of Medicine, Nice, France
  • Inserm (FR)
Venue
Cancer Research
Published
2011-06-30
Volume
71
Issue
13
Pages
4366-4372
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2164882663
Cited by
616
References
20
Citations by year
2026: 15 · 2025: 18 · 2024: 25 · 2023: 21 · 2022: 44 · 2021: 43 · 2020: 49 · 2019: 38 · 2018: 50 · 2017: 56 · 2016: 51 · 2015: 63 · 2014: 51 · 2013: 58 · 2012: 23
FWCI
18.38
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Agence Nationale de la Recherche (ANR-09-GENO-0036)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
metformin, REDD1, mTOR inhibition, p53, cell cycle arrest, prostate cancer, anticancer drug repurposing, cell transformation
MeSH terms
Animals, Cell Cycle, Humans, Male, Metformin, Mice, Transgenic, Prostatic Neoplasms, RNA, Messenger, Transcription Factors, Transfection, Tumor Suppressor Protein p53, Cyclin D1, RNA, Small Interfering, Cell Line, Tumor, Mice, AMP-Activated Protein Kinases, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1. https://app.cochat.ai/papers/10.1158/0008-5472.can-10-1769
The paper
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011). Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1. Cancer Research. https://doi.org/10.1158/0008-5472.can-10-1769

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.